AMGX.F Stock Overview
A biopharmaceutical company, engages in the research and development of gene-based medical products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AnGes, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.34 |
| 52 Week High | JP¥1.00 |
| 52 Week Low | JP¥0.34 |
| Beta | 0 |
| 1 Month Change | -10.11% |
| 3 Month Change | n/a |
| 1 Year Change | -55.29% |
| 3 Year Change | -96.16% |
| 5 Year Change | n/a |
| Change since IPO | -95.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMGX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.2% | 1.7% |
| 1Y | -55.3% | 6.2% | 26.3% |
Return vs Industry: AMGX.F underperformed the US Biotechs industry which returned 6.2% over the past year.
Return vs Market: AMGX.F underperformed the US Market which returned 26.3% over the past year.
Price Volatility
| AMGX.F volatility | |
|---|---|
| AMGX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: AMGX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AMGX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 145 | Ei Yamada | www.anges.co.jp |
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University.
AnGes, Inc. Fundamentals Summary
| AMGX.F fundamental statistics | |
|---|---|
| Market cap | US$65.72m |
| Earnings (TTM) | -US$40.79m |
| Revenue (TTM) | US$1.60m |
41.1x
P/S Ratio-1.6x
P/E RatioIs AMGX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGX.F income statement (TTM) | |
|---|---|
| Revenue | JP¥249.00m |
| Cost of Revenue | JP¥151.00m |
| Gross Profit | JP¥98.00m |
| Other Expenses | JP¥6.45b |
| Earnings | -JP¥6.35b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -29.17 |
| Gross Margin | 39.36% |
| Net Profit Margin | -2,550.20% |
| Debt/Equity Ratio | 0% |
How did AMGX.F perform over the long term?
See historical performance and comparison